T-DXd: New Standard for HER2-Low Breast Cancer

Cancer Discov. 2022 Aug 5;12(8):1828. doi: 10.1158/2159-8290.CD-NB2022-0043.

Abstract

Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer. T-DXd should be considered a new standard of care for these patients, who otherwise have limited options.

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Camptothecin / analogs & derivatives
  • Female
  • Humans
  • Immunoconjugates* / therapeutic use
  • Receptor, ErbB-2
  • Trastuzumab / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoconjugates
  • trastuzumab deruxtecan
  • Receptor, ErbB-2
  • Trastuzumab
  • Camptothecin